Moreno-Ramírez D

Language: Spanish
References: 8
Page: 5-6
PDF size: 195.30 Kb.

Text Extraction

No abstract.

REFERENCES

1. He Y, Qian H, Liu Y, Duan L, Li Y, Shi G. The roles of regulatory B cells in cancer. J Immunol Res. 2014; 2014: 215471. doi: 10.1155/2014/215471

2. Gajewski TF, Schreiber H, Fu Y-X. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013; 14(10): 1014-1022. doi: 10.1038/ni.2703

3. Zamarron BF, Chen W. Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci. 2011; 7(5): 651-658.

4. Callahan MK. Immune checkpoint therapy in melanoma. Cancer J. 2016; 22(2): 73-80. doi: 10.1097/PPO.0000000000000183

5. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015; 372(4): 320-330. doi:10.1056/NEJMoa1412082

6. Robert C, Schachter J, Long GV, Arance A, Jacques GJ, Mortier L et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015; 372(26): 2521-2532. doi: 10.1056/NEJMoa1503093

7. National Comprehensive Cancer Network clinical practice guidelines in oncology. Melanoma version 1.2018.

8. Pinedo-Donelli S, Ball PE. PD-1 y sus ligandos: importancia en dermatología. Med Cutan Iber Lat Am. 2018; 46(1): 30-37.